Minimum clinically important difference analysis confirms the efficacy of IgPro10 in CIDP: the PRIMA trial

J Peripher Nerv Syst. 2017 Jun;22(2):149-152. doi: 10.1111/jns.12204.
No abstract available

Publication types

  • Clinical Trial, Phase III
  • Letter
  • Multicenter Study

MeSH terms

  • Adult
  • Humans
  • Immunoglobulins, Intravenous / administration & dosage
  • Immunoglobulins, Intravenous / pharmacology*
  • Immunologic Factors / administration & dosage
  • Immunologic Factors / pharmacology*
  • Minimal Clinically Important Difference*
  • Outcome Assessment, Health Care / methods*
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / drug therapy*
  • Prospective Studies

Substances

  • Immunoglobulins, Intravenous
  • Immunologic Factors

Associated data

  • ClinicalTrials.gov/NCT01184846